SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Recombinant Protein
COVID-19 Spike Research.
Cat: 40589-V08B1
SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Recombinant Protein: 产品信息
纯度
> 90 % as determined by SDS-PAGE.
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
生物活性
The 2019-nCoV Spike Protein (S1+S2 ECD, His tag) can bind with Human ACE2 in functional ELISA assay.
蛋白构建
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (S1+S2 ECD) (YP_009724390.1) (Val 16-Pro1213) was expressed with a polyhistidine tag at the C-terminus.
NP No.
表达宿主
Baculovirus-Insect Cells
种属
2019-nCoV
预测 N 端
Val 16
分子量
The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (S1+S2 ECD, His tag) consists of 1209 amino acids and predicts a molecular mass of 134.36 kDa.
缓冲液
Lyophilized from sterile 20 mM Tris, 300 mM NaCl, 10 % glycerol, pH 8.0.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
运输方式
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
稳定性 & 储存条件
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
复溶
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Recombinant Protein: 图片
Measured by its binding ability in a functional ELISA. Immobilized human ACE2 protein (Fc tag) (10108-H05H) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His (40589-V08B1), the EC50 of SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His (40589-V08B1) is 400-1200 ng/mL.
SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Recombinant Protein: 别称
coronavirus spike Protein, 2019-nCoV; cov spike Protein, 2019-nCoV; ncov RBD Protein, 2019-nCoV; ncov s1 Protein, 2019-nCoV; ncov s2 Protein, 2019-nCoV; ncov spike Protein, 2019-nCoV; NCP-CoV RBD Protein, 2019-nCoV; NCP-CoV s1 Protein, 2019-nCoV; NCP-CoV s2 Protein, 2019-nCoV; NCP-CoV Spike Protein, 2019-nCoV; novel coronavirus RBD Protein, 2019-nCoV; novel coronavirus s1 Protein, 2019-nCoV; novel coronavirus s2 Protein, 2019-nCoV; novel coronavirus spike Protein, 2019-nCoV; RBD Protein, 2019-nCoV; S1 Protein, 2019-nCoV; S2 Protein, 2019-nCoV; Spike RBD Protein, 2019-nCoV
Coronavirus spike 背景信息
The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.
参考文献
- Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
- Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
- Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.
SARS Coronavirus spike 蛋白
2019-nCoV Coronavirus spike 蛋白
MERS-CoV Coronavirus spike 蛋白
HCoV-HKU1 Coronavirus spike 蛋白
-
Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen MicroarrayAuthorDe Assis, RR;Jain, A;Nakajima, R;Jasinskas, A;Year2020JournalBioRxiv
-
Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen MicroarrayAuthorKhan, S;Nakajima, R;Jain, A;De Assis, RR;Jasinskas, A;Year2020JournalBioRxiv
-
Cholesterol Metabolism--Impact for SARS-CoV-2 Infection Prognosis, Entry, and Antiviral TherapiesAuthorWei, C;Wan, L;Zhang, Y;Fan, C;Yan, Q;Yang, X;Gong, J;Year2020JournalmedRxiv
-
COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in salivaAuthorRandad, PR;Pisanic, N;Kruczynski, K;Manabe, YC;Year2020JournalmedRxiv
-
Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike GlycoproteinAuthorSong, Y;Song, J;Wei, X;Huang, M;Sun, M;Zhu, L;Lin, B;Shen, H;Zhu, Z;Yang, C;Year2020JournalChemRxiv
-
Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike proteinAuthorFeng, S;Luan, X;Wang, Y;Wang, H;Zhang, Z;Wang, Y;Tian, Z;Liu, M;Xiao, Y;Zhao, Y;Zhou, R;Zhang, S;Year2020JournalInfect. Genet. Evol.
-
Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding DomainAuthorChi, X;Liu, X;Wang, C;Zhang, X;Ren, L;Jin, Q;Wang, J;Year2020JournalbioRxiv
-
Immunogenicity of a DNA vaccine candidate for COVID-19AuthorSmith, TRF;Patel, A;Ramos, S;Elwood, D;Zhu, X;Yan, J;Gary, EN;Walker, SN;Schultheis, K;Purwar, M;Xu, Z;Walters, J;Bhojnagarwala, P;Yang, M;Chokkalingam, N;Pezzoli, P;Parzych, E;Reuschel, EL;Doan, A;Tursi, N;Vasquez, M;Choi, J;Tello-Ruiz, E;Maricic, I;Bah, MA;Wu, Y;Amante, D;Park, DH;Dia, Y;Ali, AR;Zaidi, FI;Generotti, A;Kim, KY;Herring, TA;Reeder, S;Andrade, VM;Buttigieg, K;Zhao, G;Wu, JM;Li, D;Bao, L;Liu, J;Deng, W;Qin, C;Brown, AS;Khoshnejad, M;Wang, N;Chu, J;Wrapp, D;McLellan, JS;Muthumani, K;Wang, B;Carroll, MW;Kim, JJ;Boyer, J;Kulp, DW;Humeau, LMPF;Weiner, DB;Broderick, KE;Year2020JournalNat Commun
-
Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cellsAuthorCao, Y;Su, B;Guo, X;Sun, W;Deng, Y;Bao, L;Zhu, Q;Zhang, X;Zheng, Y;Geng, C;Chai, X;He, R;Li, X;Lv, Q;Zhu, H;Deng, W;Xu, Y;Wang, Y;Qiao, L;Tan, Y;Song, L;Wang, G;Du, X;Gao, N;Liu, J;Xiao, J;Su, XD;Du, Z;Feng, Y;Qin, C;Qin, C;Jin, R;Xie, XS;Year2020JournalCell
-
SARS-CoV-2 spike protein binds heparan sulfate in a length-and sequence-dependent mannerAuthorLiu, L;Chopra, P;Li, X;Wolfert, MA;Tompkins, SM;Year2020JournalbioRxivApplicationSPR
-
Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass SpectrometryAuthorZhang, Y;Zhao, W;Mao, Y;Wang, S;Zhong, Y;Su, T;Year2020JournalbioRxiv
-
Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domainAuthorWalter, JD;Hutter, CAJ;Zimmermann, I;Earp, J;Egloff, P;Year2020JournalBioRxiv
-
Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine developmentAuthorHuang, S;Tai, C;Hsu, Y;Cheng, D;Hung, S;Chai, K;Wang, Y;Wang, J;Year2020JournalBiomedical Journal
-
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessAuthorCorbett, K;Edwards, D;Leist, S;Abiona, O;Boyoglu-Barnum, S;Gillespie, R;Himansu, S;Schäfer, A;Ziwawo, C;DiPiazza, A;Dinnon, K;Elbashir, S;Shaw, C;Woods, A;Fritch, E;Martinez, D;Bock, K;Minai, M;Nagata, B;Hutchinson, G;Bahl, K;Garcia-Dominguez, D;Ma, L;Renzi, I;Kong, W;Schmidt, S;Wang, L;Zhang, Y;Stevens, L;Phung, E;Chang, L;Loomis, R;Altaras, N;Narayanan, E;Metkar, M;Presnyak, V;Liu, C;Louder, M;Shi, W;Leung, K;Yang, E;West, A;Gully, K;Wang, N;Wrapp, D;Doria-Rose, N;Stewart-Jones, G;Bennett, H;Nason, M;Ruckwardt, T;McLellan, J;Denison, M;Chappell, J;Moore, I;Morabito, K;Mascola, J;Baric, R;Carfi, A;Graham, B;Year2020JournalbioRxivApplicationimmunization
-
SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patientsAuthorLei, H;Ye, F;Liu, X;Huang, Z;Ling, S;Jiang, Z;Cheng, J;Huang, X;Wu, Q;Wu, S;Xie, Y;Xiao, C;Ye, D;Yang, Z;Li, Y;Leung, NHL;Cowling, BJ;He, J;Wong, SS;Zanin, M;Year2020JournalInfluenza Other Respir VirusesApplicationElisa
-
SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patientsAuthorWalker, S;Chokkalingam, N;Reuschel, E;Purwar, M;Xu, Z;Gary, E;Kim, K;Schultheis, K;Walters, J;Ramos, S;Smith, T;Broderick, K;Tebas, P;Patel, A;Weiner, D;Kulp, D;Year2020JournalbioRxivApplicationElisa
-
Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patientsAuthorSteiner, D;Cognetti, J;Luta, E;Klose, A;Bucukovski, J;Bryan, M;Schmuke, J;Nguyen-Contant, P;Sangster, M;Topham, D;Miller, B;Year2020JournalbioRxiv
-
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patientAuthorZhou, D;Duyvesteyn, H;Chen, C;Huang, C;Chen, T;Shih, S;Lin, Y;Cheng, C;Cheng, S;Huang, Y;Lin, T;Ma, C;Huo, J;Carrique, L;Malinauskas, T;Ruza, R;Shah, P;Tan, T;Rijal, P;Donat, R;Godwin, K;Buttigieg, K;Tree, J;Radecke, J;Paterson, N;Supasa, P;Mongkolsapaya, J;Screaton, G;Carroll, M;Jaramillo, J;Knight, M;James, W;Owens, R;Naismith, J;Townsend, A;Fry, E;Zhao, Y;Ren, J;Stuart, D;Huang, K;Year2020JournalbioRxivApplicationElisa
-
Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteinsAuthorShi, Y;Shi, J;Sun, L;Tan, Y;Wang, G;Guo, F;Hu, G;Fu, Y;Fu, Z;Xiao, S;Peng, G;Year2020JournalbioRxivApplicationAnimal immunization; Elisa
-
A single dose of an adenovirus-vectored vaccine provides complete protection of the upper and lower respiratory tracts against SARS-CoV-2 challengeAuthorWu, S;Zhong, G;Zhang, J;Shuai, L;Zhang, Z;Wen, Z;Wang, B;Zhao, Z;Song, X;Chen, Y;Liu, R;Fu, L;Zhang, J;Guo, Q;Wang, C;Yang, Y;Fang, T;Lv, P;Wang, J;Xu, J;Li, J;Yu, C;Hou, L;Bu, Z;Chen, W;Year2020JournalResearch Square
-
Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactionsAuthorKim, SY;Jin, W;Sood, A;Montgomery, DW;Grant, OC;Fuster, MM;Fu, L;Dordick, JS;Woods, RJ;Zhang, F;Linhardt, RJ;Year2020JournalAntiviral Res.ApplicationSPR
-
SARS-CoV-2 surveillance for a non-human primate breeding research facilityAuthorYee, JL;Van Rompay, KKA;Carpenter, AB;Nham, PB;Halley, BM;Iyer, SS;Hartigan-O'Connor, DJ;Miller, CJ;Roberts, JA;Year2020JournalJ. Med. Primatol.ApplicationElisa
-
A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodiesAuthorAcharya, P;Williams, W;Henderson, R;Janowska, K;Manne, K;Parks, R;Deyton, M;Sprenz, J;Stalls, V;Kopp, M;Mansouri, K;Edwards, RJ;Meyerhoff, RR;Oguin, T;Sempowski, G;Saunders, K;Haynes, BF;Year2020JournalbioRxivApplicationElisa
-
A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodiesAuthorAcharya, P;Williams, W;Henderson, R;Janowska, K;Manne, K;Parks, R;Deyton, M;Sprenz, J;Stalls, V;Kopp, M;Mansouri, K;Edwards, RJ;Meyerhoff, RR;Oguin, T;Sempowski, G;Saunders, K;Haynes, BF;Year2020JournalbioRxiv
-
Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potencyAuthorDu, S;Cao, Y;Zhu, Q;Wang, G;Du, X;He, R;Xu, H;Zheng, Y;Wang, B;Bai, Y;Ji, C;Yisimayi, A;Wang, Q;Gao, N;Xie, X;Su, X;Xiao, J;Year2020JournalbioRxiv
-
Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody ResponseAuthorRouthu, N;Gangadhara, S;Cheedarla, N;Shiferaw, A;Rahman, S;Sahoo, A;Shi, P;Menachery, V;Floyd, K;Fischinger, S;Atyeo, C;Alter, G;Suthar, M;Amara, R;Year2020JournalbioRxiv
-
Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike ProteinsAuthorZhang, Y;Zhao, W;Mao, Y;Chen, Y;Wang, S;Zhong, Y;Su, T;Gong, M;Du, D;Lu, X;Cheng, J;Yang, H;Year2020JournalbioRxivApplicationN-glycosylation Characterization by MS
-
Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and EndocytosisAuthorGorshkov, K;Susumu, K;Chen, J;Xu, M;Pradhan, M;Zhu, W;Hu, X;Breger, JC;Wolak, M;Oh, E;Year2020JournalACS Nano
-
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2AuthorClausen, TM;Sandoval, DR;Spliid, CB;Pihl, J;Painter, CD;Thacker, BE;Glass, CA;Narayanan, A;Majowicz, SA;Zhang, Y;Torres, JL;Golden, GJ;Porell, R;Garretson, AF;Laubach, L;Feldman, J;Yin, X;Pu, Y;Hauser, B;Caradonna, TM;Kellman, BP;Martino, C;Gordts, PLSM;Leibel, SL;Chanda, SK;Schmidt, AG;Godula, K;Jose, J;Corbett, KD;Ward, AB;Carlin, AF;Esko, JD;Year2020JournalbioRxiv
If you couldn't find the specific citation, you can:
